Kinney T B, Valji K, Rose S C, Yeung D D, Oglevie S B, Roberts A C, Ward D M
Department of Radiology, University of California San Diego Medical Center, USA.
J Vasc Interv Radiol. 2000 Oct;11(9):1143-52. doi: 10.1016/s1051-0443(07)61355-4.
To compare the frequency and extent of pulmonary embolism (PE) occurring during pulse-spray pharmacomechanical thrombolysis (PSPMT) of clotted hemodialysis grafts with use of either urokinase (UK) or heparinized saline (HS). Postintervention primary patency and complication rates were compared for each method of thrombolysis.
Twenty-seven patients were enrolled in this prospective, randomized, double-blind study evaluating PE with two PSPMT agents. The doses of heparin were similar between groups. The only variable was that one group of patients received UK and the other received HS. In two cases, the venous anastomosis could not be crossed. Eleven patients were treated with UK and 14 with HS. Nuclear medicine perfusion lung scans were performed before treatment and after graft declotting procedures. Lung perfusion was quantified to 10% of a pulmonary segment (0 = normal perfusion, 1 = segmental perfusion defect), with nine segments counted for each lung.
Baseline nuclear medicine perfusion lung scan results were abnormal (> or = 20% segmental perfusion defect) in 19 patients (70.4%). New PE (one or more pulmonary segments) occurred in two patients treated with UK (18.2%) and nine patients treated with HS (64.3%; P = .04). All cases of PE were asymptomatic. Quantitative global pulmonary perfusion analyses revealed that treatment with UK improved flow to 0.2 +/- 2.0 pulmonary segments, whereas treatment with HS decreased perfusion to 1.0 +/- 1.7 segments (P = .16, NS). Although postintervention primary patency rates were similar according to life-table analysis (P = .76, NS), complication rates were higher with use of HS (n = 4, 28.6%) than with use of UK (n = 2, 18.2%) (P = .6, NS).
All PE were asymptomatic during PSPMT, but treatment with UK reduced the rate of PE and tended to result in smaller defects in lung scan results. Most patients undergoing hemodialysis have abnormal baseline perfusion scan results, but PSPMT with UK improved many of them. The postintervention primary patency rates were similar between groups, but complications were more frequent after treatment with HS.
比较在使用尿激酶(UK)或肝素盐水(HS)对凝血的血液透析移植物进行脉冲喷射药物机械溶栓(PSPMT)过程中发生肺栓塞(PE)的频率和程度。比较每种溶栓方法干预后的初次通畅率和并发症发生率。
27例患者参与了这项前瞻性、随机、双盲研究,评估两种PSPMT药物对PE的影响。两组肝素剂量相似。唯一的变量是一组患者接受UK,另一组接受HS。有2例患者的静脉吻合口无法通过。11例患者接受UK治疗,14例接受HS治疗。在治疗前和移植物血栓清除术后进行核医学肺灌注扫描。肺灌注定量为肺段的10%(0 = 正常灌注,1 = 节段性灌注缺损),每侧肺计算9个节段。
19例患者(70.4%)的基线核医学肺灌注扫描结果异常(节段性灌注缺损≥20%)。接受UK治疗的2例患者(18.2%)和接受HS治疗的9例患者(64.3%)出现新的PE(一个或多个肺段)(P = 0.04)。所有PE病例均无症状。定量整体肺灌注分析显示,UK治疗使血流改善至0.2±2.0个肺段,而HS治疗使灌注减少至1.0±1.7个节段(P = 0.16,无统计学意义)。尽管根据生存表分析干预后的初次通畅率相似(P = 0.76,无统计学意义),但使用HS的并发症发生率(n = 4,28.6%)高于使用UK的并发症发生率(n = 2,18.2%)(P = 0.6,无统计学意义)。
PSPMT期间所有PE均无症状,但UK治疗降低了PE发生率,并倾向于使肺扫描结果中的缺损更小。大多数接受血液透析的患者基线灌注扫描结果异常,但UK进行的PSPMT改善了其中许多患者的情况。两组干预后的初次通畅率相似,但HS治疗后并发症更频繁。